Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367962 · ClinicalTrials.gov registry record · Phase 1
Detection of Graft Versus Host Disease With [18F]F-AraG
A Phase 1 study, sponsored by CellSight Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03367962: Completed Phase 1 study, sponsored by CellSight Technologies.
NCT03367962 is a Phase 1 study that has completed, run by CellSight Technologies. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03367962, a Phase 1 study, has completed, sponsored by CellSight Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single-center imaging study to determine utility of in vivo imaging with \[18F\]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD. \[18F\]F-AraG PET scans will be compared to biopsy results to correlate T cell accumulation which is implicated in the disease. High risk patients will be followed to verify predictive potential of \[18F\]F-AraG.
Primary Outcome
Acute GVHD severity was graded using the Mount Sinai Acute GVHD International Consortium (MAGIC) criteria (Grades I-IV). Grades were assigned based on organ involvement documented in the clinical chart and biopsy review at the time of the PET/CT scan. We reported the number of participants within each grade.
Interventions
- DRUG [18F]F-Ara-G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-05-15 |
| Est. Completion | 2023-10-21 |
| Phase | Phase 1 |
What the finished NCT03367962 record still lists
NCT03367962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F]F-Ara-G is the first listed.
NCT03367962 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03367962 about?
NCT03367962 is a clinical study titled "Detection of Graft Versus Host Disease With [18F]F-AraG". This is a single-center imaging study to determine utility of in vivo imaging with \[18F\]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD. \[18F\]F-AraG PE...
What is the current status of trial NCT03367962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-05-15. Estimated completion is 2023-10-21.
What interventions are being tested in trial NCT03367962?
The interventions under investigation include: [18F]F-Ara-G (DRUG).
Who is sponsoring clinical trial NCT03367962?
This trial is sponsored by CellSight Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03367962's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI